Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
November 06, 2025
Not intended for U.S. and UK Media – Late-Breaking data from FINE-ONE Phase III study presented at ASN Kidney Week 2025
Finerenone showed statistically significant reduction of UACR in adults with chronic kidney disease associated with type 1 diabetes
October 24, 2025
Not intended for U.S. and UK Media
Bayer’s Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause
Discover More
